This study's aim was to investigate iron (Fe) and zinc (Zn) concentration in the soil, forage crops, and sheep blood with respect to the seasonal availability of these metals. Soil, forage, and sheep blood samples were sampled from five different locations in Chakwal (Pidh, Tobar, Ratoccha, Choa Saiden Shah-Kalar Kahar road, and Choa Saiden Shan-Chakwal Road) during two seasons, i.e., winter and summer. All the samples were processed through wet acid digestion for evaluation of metal contents. Because of proximity of site-1 and site-2 to coal mines, higher Fe concentration was observed than Zn. Overall, varied Fe concentrations obtained in soil were 12.95-24.31 mg/kg, 1.29-9.61 mg/kg in forage and 1.17-24 mg/l in blood, whereas Zn values were 1.04-31.9 mg/kg, 1.96-7.02 mg/kg, and 0.16-6.52 mg/l for soil, forages, and blood respectively. The pollution load index value for both Fe (0.01-0.14 mg/kg) and Zn (0.02-0.72 mg/kg) was lesser than 1. Bio-concentration (0.09-2.64mg/kg) and enrichment factor (0.08-7.51 mg/kg) were showing efficient transfer of metals through the food chain. Daily intake and health risk index values of iron were ranged from 0.01 to 1.1 mg/kg/day and 0.02 to 1.05 mg/kg/day. There was a probable chance of upsurge in metal values in coming years due to continued mining activities. Anthropogenic input, mainly mining activities in the study area, have increased the Fe and Zn content in the environment which can ultimately find their way up the food chain, thereby risking the health of grazing livestock.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11356-021-16756-4DOI Listing

Publication Analysis

Top Keywords

health risk
8
soil forage
8
sheep blood
8
choa saiden
8
food chain
8
mining activities
8
mg/kg
7
study contamination
4
contamination assessment
4
assessment health
4

Similar Publications

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Background: Traumatic Brain Injury (TBI) is one of the most common nonheritable causes of Alzheimer's disease (AD). However, there is lack of effective treatment for both AD and TBI. We posit that network-based integration of multi-omics and endophenotype disease module coupled with large real-world patient data analysis of electronic health records (EHR) can help identify repurposable drug candidates for the treatment of TBI and AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: Rater change is inevitable in often lengthy clinical trials in Alzheimer's disease. Other groups have previously assessed the impact of rater change on data variability. Their conclusions varied, possibly due to differing methodologies (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!